Skip to main content

Table 4 Univariate and multivariate analysis of factors associated with clinical cure in 181 patients with CRO infections

From: Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections

Characteristic Univariate analysis Multivariate analysis
Odds ratio (95% confidence interval) P-value Odds ratio (95% confidence interval) P-value
Age (years) 1.006 (0.987, 1.026) 0.547   
Male 1.111 (0.563, 2.193) 0.761   
APACHE II score 0.944 (0.897, 0.993) 0.027 0.880 (0.811 0.955) 0.002
Comorbidities  
 Chronic heart failure 0.587 (0.322, 1.067) 0.081   
 Diabetes mellitus 0.975 (0.542, 1.755) 0.933   
 COPD 0.761 (0.390, 1.483) 0.422   
 Chronic kidney disease 1.069 (0.574, 1.990) 0.833   
 Immunosuppressive status 1.017 (0.550, 1.879) 0.957   
Infection types
 Pneumonia 0.595 (0.328, 1.078) 0.087   
 Bloodstream infection 0.499 (0.235, 1.061) 0.071   
 Multiple site infections 0.530 (0.248, 1.131) 0.101   
Responsible pathogens
 K.P 0.893 (0.498, 1.603) 0.705   
 P.A 0.508 (0.258, 1.000) 0.050   
 E. coli 2.395 (0.797, 7.197) 0.120   
 A.B 0.236 (0.049, 1.143) 0.073   
Multiple bacterial infections 0.393 (0.144, 1.073) 0.068   
Polymyxin B dose 2.367 (1.403, 3.991) 0.001 1.376 (0.558, 3.394) 0.488
Initial treatment 2.169 (1.177, 3.995) 0.013 1.643 (0.662, 4.077) 0.284
Duration of polymyxin B treatment(days) 1.168 (1.103, 1.236) ≤ 0.001 1.157 (1.077, 1.243) ≤ 0.001
Antibiotic combination 3.987 (1.074, 14.811) 0.039 3.853 (0.627, 23.668) 0.145
Microbiological eradication 26.541 (11.510, 61.202) ≤ 0.001 21.345 (8.007, 56.901) ≤ 0.001
  1. A.B.: Acinetobacter baumannii; APACHE II: acute physiology and chronic health evaluation II; COPD: chronic obstructive pulmonary disease; E. coli: Escherichia coli; E.fm: Enterococcus faecium; K.P.: Klebsiella pneumonia; P.A.: Pseudomonas aeruginosa